SLC5A2 and heart failure: Understanding this mechanism is clearly essential as the use of SGLT2 inhibitors in non-diabetics is increasing and a better understanding may allow refinement of therapeutic approaches in both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF).